🎉 M&A multiples are live!
Check it out!

Clearside Biomedical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Clearside Biomedical and similar public comparables like Benevolent AI, Vivoryon Therapeutics, and Pharming.

Clearside Biomedical Overview

About Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.


Founded

2011

HQ

United States of America
Employees

32

Financials

LTM Revenue $1.4M

LTM EBITDA -$30.4M

EV

$42.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Clearside Biomedical Financials

Clearside Biomedical has a last 12-month revenue of $1.4M and a last 12-month EBITDA of -$30.4M.

In the most recent fiscal year, Clearside Biomedical achieved revenue of $1.7M and an EBITDA of -$24.3M.

Clearside Biomedical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Clearside Biomedical valuation multiples based on analyst estimates

Clearside Biomedical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $8.2M $1.7M XXX XXX XXX
Gross Profit $1.1M $7.9M XXX XXX XXX
Gross Margin 14% 473% XXX XXX XXX
EBITDA -$23.1M -$24.3M XXX XXX XXX
EBITDA Margin -280% -1463% XXX XXX XXX
Net Profit -$32.9M -$32.5M XXX XXX XXX
Net Margin -401% -1952% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Clearside Biomedical Stock Performance

As of April 15, 2025, Clearside Biomedical's stock price is $1.

Clearside Biomedical has current market cap of $61.7M, and EV of $42.4M.

See Clearside Biomedical trading valuation data

Clearside Biomedical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$42.4M $61.7M XXX XXX XXX XXX $-0.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Clearside Biomedical Valuation Multiples

As of April 15, 2025, Clearside Biomedical has market cap of $61.7M and EV of $42.4M.

Clearside Biomedical's trades at 29.8x LTM EV/Revenue multiple, and -1.4x LTM EBITDA.

Analysts estimate Clearside Biomedical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Clearside Biomedical and 10K+ public comps

Clearside Biomedical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $42.4M XXX XXX XXX
EV/Revenue 25.5x XXX XXX XXX
EV/EBITDA -1.7x XXX XXX XXX
P/E -1.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Clearside Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Clearside Biomedical Valuation Multiples

Clearside Biomedical's NTM/LTM revenue growth is 70%

Clearside Biomedical's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Clearside Biomedical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Clearside Biomedical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Clearside Biomedical and other 10K+ public comps

Clearside Biomedical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -80% XXX XXX XXX XXX
EBITDA Margin -1463% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1393% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 710% XXX XXX XXX XXX
R&D Expenses to Revenue 1117% XXX XXX XXX XXX
Opex to Revenue 1827% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Clearside Biomedical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Clearside Biomedical M&A and Investment Activity

Clearside Biomedical acquired  XXX companies to date.

Last acquisition by Clearside Biomedical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Clearside Biomedical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Clearside Biomedical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Clearside Biomedical

When was Clearside Biomedical founded? Clearside Biomedical was founded in 2011.
Where is Clearside Biomedical headquartered? Clearside Biomedical is headquartered in United States of America.
How many employees does Clearside Biomedical have? As of today, Clearside Biomedical has 32 employees.
Who is the CEO of Clearside Biomedical? Clearside Biomedical's CEO is Dr. George Lasezkay, J.D.,Pharm.D..
Is Clearside Biomedical publicy listed? Yes, Clearside Biomedical is a public company listed on NAS.
What is the stock symbol of Clearside Biomedical? Clearside Biomedical trades under CLSD ticker.
When did Clearside Biomedical go public? Clearside Biomedical went public in 2016.
Who are competitors of Clearside Biomedical? Similar companies to Clearside Biomedical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Clearside Biomedical? Clearside Biomedical's current market cap is $61.7M
What is the current revenue of Clearside Biomedical? Clearside Biomedical's last 12-month revenue is $1.4M.
What is the current EBITDA of Clearside Biomedical? Clearside Biomedical's last 12-month EBITDA is -$30.4M.
What is the current EV/Revenue multiple of Clearside Biomedical? Current revenue multiple of Clearside Biomedical is 29.8x.
What is the current EV/EBITDA multiple of Clearside Biomedical? Current EBITDA multiple of Clearside Biomedical is -1.4x.
What is the current revenue growth of Clearside Biomedical? Clearside Biomedical revenue growth between 2023 and 2024 was -80%.
Is Clearside Biomedical profitable? Yes, Clearside Biomedical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.